Ultragenyx Trial Fails
Ultragenyx shares tumble 45 percent after late-stage trial for Angelman treatment misses key endpoints.
Anonymous
Key Points
1
ASPIRE failed to meet the primary endpoint (change from Baseline in Bayley-4 cognitive raw score) and the key secondary endpoint (net response in the Multidomain Responder Index, MDRI) for apazunersen in Angelman syndrome.
2
William Blair analyst Sami Corwin warned that even if Ultragenyx’ Aurora trial meets its primary endpoint, commercialization would be challenging due to the limited size of the addressable population.
3
Angelman syndrome affects about 1 in 21,000 births worldwide, and apazunersen is designed to reactivate the paternal UBE3A gene to boost brain UBE3A protein levels; there are currently no approved disease-modifying treatments.
4
The results also serve as a warning for Ionis’ obudanersen (ION582), with the phase 3 REVEAL trial results due in the second half of 2027.
Ultragenyx Pharmaceutical's stock crashed 45% after its Phase 3 Aspire trial of apazunersen failed to treat Angelman syndrome, missing both the primary and key secondary endpoints Yahoo Finance. The drug was designed to reactivate a faulty gene and boost brain protein levels in patients with this rare genetic disorder that affects about 1 in 21,000 births worldwide Pharma Phorum.
This is Ultragenyx's second consecutive late-stage trial failure, raising serious questions about the company's pipeline and future. Pharma Exec noted that shares fell nearly 45%, and the company is now implementing significant expense reductions to survive the setback Pharma Exec. Currently, Angelman syndrome has no approved disease-modifying treatments, leaving patients without meaningful options.
A Major Setback for Rare Disease Treatment
Apazunersen failed to improve cognitive development in Angelman patients, missing the primary goal of boosting Bayley-4 cognitive raw scores Pharma Exec. It also missed the key secondary endpoint measuring response across multiple domains. The failure leaves Ultragenyx without a validated treatment path for a disorder with no current approved options, making this a crushing blow for the company and patients waiting for help.
Second Pipeline Failure in a Row Shakes Investor Confidence
This trial miss is the company's second major late-stage failure, intensifying investor concerns Barron's. Yahoo Finance reported the stock hit a record low, erasing recent gains entirely. The repeated setbacks signal deeper problems with Ultragenyx's drug development strategy and raise doubts about management's ability to advance candidates through testing successfully.
Commercialization Challenges Even If Aurora Succeeds
William Blair analyst Sami Corwin warned that even if Ultragenyx's Aurora trial meets its primary endpoint, selling apazunersen would be extremely difficult Barron's. The addressable patient population for Angelman is simply too small to generate meaningful revenue. This means the company may struggle to recoup development costs even with a positive trial, making future investment in the program harder to justify.
Broader Warning for Competing Angelman Programs
The Aspire failure also signals trouble ahead for Ionis Pharmaceuticals' obudanersen (ION582), which targets the same disease mechanism Pharma Exec. Ionis' Phase 3 REVEAL trial results are due in the second half of 2027. If both companies' approaches fail, Angelman patients will face continued waiting for any disease-modifying treatment option.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
16
Articles
73
Reach
89
A
AnonymousAuthor
